Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Y. Kito, T. Yamada, T. Matsumoto, H. Yasui, K. Murata, A. Makiyama, H. Hara, E. Baba, K. Nishio, K. Yoshimura, S. Hironaka, K. Muro, K. Yamazaki

研究成果: Contribution to journalArticle

元の言語英語
ページ(範囲)viii201
ジャーナルAnnals of oncology : official journal of the European Society for Medical Oncology
29
DOI
出版物ステータス出版済み - 10 1 2018

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

これを引用